• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New strategies for osteoporosis patients previously managed with strontium ranelate
The aim of this article is to describe potential alternatives to patients no longer eligible for management with strontium ranelate for osteoporosis according to the recommendations by the European Medicines Agency. A systematic search of Pubmed was done for papers on fracture efficacy of various treatments for osteoporosis, and potential harms especially in terms of cardiovascular events and stroke. The results showed that drugs more efficacious in terms of relative risk reduction of fractures than strontium ranelate were alendronate, risedronate, zoledronate, and denosumab. Raloxifene, as for strontium, may be associated...
Source: Therapeutic Advances in Musculoskeletal Disease - November 19, 2014 Category: Orthopaedics Authors: Vestergaard, P. Tags: Reviews Source Type: research

Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score –Matched Cohort Study
ABSTRACTZoledronic acid (ZA) is an effective agent in osteoporosis and malignancy ‐related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new‐user, active comp arator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)‐matched to i...
Source: Journal of Bone and Mineral Research - November 2, 2020 Category: Orthopaedics Authors: Kristin M D'Silva, Sara Jane Cromer, Elaine W Yu, Michael Fischer, Seoyoung C Kim Tags: Original Article Source Type: research

Cardiovascular safety of denosumab across multiple indications: a systematic review and meta ‐analysis of randomized trials
AbstractThe cardiovascular safety of denosumab has not yet been evaluated in a systematic review. This systematic review and meta ‐analysis sought to quantify the number of randomized controlled trials (RCTs) of denosumab (against comparators) reporting cardiovascular adverse events (CAEs) and examine the balance of CAEs between treatment arms. MEDLINE, Embase andclinicaltrials.gov were searched from inception to 26th October 2019 for RCTs of denosumab versus comparators for any indication. Included trials were randomized, enrolled ≥100 participants and reported bone‐related outcomes. Primary outcome for analysis was...
Source: Journal of Bone and Mineral Research - August 10, 2020 Category: Orthopaedics Authors: Alexander H. Seeto, Bo Abrahamsen, Peter R. Ebeling, Alexander J. Rodr íguez Tags: Original Article Source Type: research